BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

This early-phase study is testing a new drug called BXCL701 in patients with acute myeloid leukemia (AML, a blood cancer) or a related bone marrow disorder (myelodysplastic syndrome, MDS) that has returned or stopped responding to previous treatments. **You may be eligible if...** - You are 18 or older - You have relapsed or treatment-resistant AML, or a high-risk form of MDS (MDS-EB-2) that has not responded to at least 4 cycles of standard therapy - Your performance status and organ function (kidney, liver, heart) are within acceptable ranges - If HIV-positive, your viral load is undetectable and you are on a stable treatment regimen **You may NOT be eligible if...** - You are not in good enough health to tolerate treatment - You have severely low kidney, liver, or heart function (outside study parameters) - You have very high white blood cell counts on the first day of treatment (above 25,000/µL) Talk to your doctor to see if this trial is right for you.